BRAIN Biotech AG (XTER:BNN) Cash-to-Debt : N/A (As of Jun. 2024)

BRAIN Biotech AG Cash-to-Debt Chart

BRAIN Biotech AG Annual Data
	Trend	Sep15	Sep16	Sep17	Sep18	Sep19	Sep20	Sep21	Sep22	Sep23
Cash-to-Debt		Get a 7-Day Free Trial				No Debt	No Debt	9.33	2.93	1.16

BRAIN Biotech AG Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Cash-to-Debt	Get a 7-Day Free Trial															N/A	1.16	N/A	2.42	N/A

Competitive Comparison of BRAIN Biotech AG's Cash-to-Debt

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BRAIN Biotech AG's Cash-to-Debt Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Cash-to-Debt falls into.

BRAIN Biotech AG Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BRAIN Biotech AG's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

BRAIN Biotech AG's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG  (XTER:BNN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BRAIN Biotech AG Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BRAIN Biotech AG Business Description